SCHEMBL4036162

SCHEMBL4036162

N#Cc1ccc(-n2nc(Nc3ccc(N4CCOCC4)cc3)nc2N)nc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 12/20 0.72
KIT P10721 6/20 0.72
IRAK4 Q9NWZ3 4/20 0.72
AURKA O14965 1/20 0.72
AXL P30530 4/20 0.55
JAK2 O60674 3/20 0.53
BACE1 P56817 4/20 0.49
JAK3 P52333 2/20 0.47
ABL1 P00519 1/20 0.47
LCK P06239 1/20 0.47
LYN P07948 1/20 0.47
MET P08581 1/20 0.47
PDGFRB P09619 1/20 0.47
SRC P12931 1/20 0.47
FGFR3 P22607 1/20 0.47
KDR P35968 1/20 0.47
TEK Q02763 1/20 0.47
KARS1 Q15046 1/20 0.47
SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4044990 0.87 FLT3 (0.62) FLT3KITIRAK4AURKAAXL
SCHEMBL4040681 0.85 FLT3 (0.70) FLT3KITIRAK4AURKAAXL
SCHEMBL4048022 0.84 FLT3 (1.00) FLT3KITIRAK4AURKAJAK2
SCHEMBL4041073 0.82 FLT3 (0.67) FLT3KITIRAK4AURKAAXL
SCHEMBL4046201 0.81 FLT3 (0.75) FLT3KITIRAK4AURKAAXL
SCHEMBL4037659 0.81 FLT3 (0.66) FLT3KITIRAK4AURKAAXL
SCHEMBL2085464 0.80 FLT3 (0.54) FLT3KITIRAK4AURKAAXL
SCHEMBL4045933 0.80 FLT3 (0.70) FLT3KITIRAK4AURKAAXL
SCHEMBL4037409 0.80 FLT3 (1.00) FLT3KITIRAK4AURKAAXL
SCHEMBL4038186 0.80 FLT3 (0.70) FLT3KITIRAK4AURKAAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885KIT 1144/4885IRAK4 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.